The Global Innovation Model for Antibiotics Needs Reinvention

Journal of Law, Medicine and Ethics

Volumn 43, Issue S3, 2015, Pages 22-26

  Balasegaram, Manica ^a   Clift, Charles ^b   Røttingen, John Arne ^c,d  

^a Access Campaign   (France)

^b ROYAL INSTITUTE OF INTERNATIONAL AFFAIRS   (United Kingdom)

^c UNIVERSITY OF OSLO   (Norway)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; DRUG DEVELOPMENT; DRUG INDUSTRY; HUMAN; NONBIOLOGICAL MODEL;

ANTI-BACTERIAL AGENTS; DRUG DISCOVERY; DRUG INDUSTRY; DRUG RESISTANCE, MICROBIAL; HUMANS; MODELS, ORGANIZATIONAL;

EID: 84938560918     PISSN: 10731105     EISSN: 1748720X     Source Type: Journal    
DOI: 10.1111/jlme.12270     Document Type: Article

References (15)

1. M. S. Butler, M. A. Blaskovich, and M. A. Cooper, "Antibiotics in the Clinical Pipeline in 2013, " Journal of Antibiotics 66 (2013): 571-599.
2. K. Outterson, New Business Models for Sustainable Antibiotics (Chatham House, London: Royal Institute of International Affairs, 2014).
3. K. Outterson, J. H. Powers, G. W. Daniel, and M. B. McClellan, "Repairing the Broken Market for Antibiotic Innovation, " Health Affairs 34, no. 2 (2015): 277-285.
4. Report on the event, "Best Use of Medicines Legislation to Bring New Antibiotics to Patients and Combat the Resistance Problem, " European Medicines Agency, London, November 2013, available at (last visited May 14, 2015).
5. World Health Organization, Research and Development to Meet Health Needs in Developing Countries: Strengthening Global Financing and Coordination, Report of the Consultative Expert Working Group on Research and Development: Financing and Coordination (2012), available at (last visited May 14, 2015).
6. A. Hollis and P. Maybarduk, "Antibiotic Resistance Is a Tragedy of the Commons That Necessitates Global Cooperation, " Journal of Law, Medicine & Ethics 43, no. 2 (2015): available via aslme.org.
7. E. Jaczynska, K. Outterson, and J. Mestre-Farrandiz, Business Model Options for Antibiotics: Learning from Other Industries (Big Innovation Centre/Chatham House, London: Royal Institute of International Affairs, 2015);Chatham House Working Group, New Antibiotic Business Model (Chatham House, London: Royal Institute of International Affairs, 2015).
8. Longitude Prize, available at https://longitudeprize.org/ (last visited May 14, 2015);Gavi, "Pneumococcal AMC, " available at (last visited May 14, 2015).
9. Follow-up of the report on the Consultative Expert Working Group on Research and Development: Financing and Coordination, available at (last visited May 14, 2015).
10. S. J. Hoffmann, K. Outterson, J. A. Røttingen, O. Cars, C. Clift, Z. Rizvi, F. Rotberg, G. Tomson, and A. Zorset, "An International Legal Framework to Address Antimicrobial Resistance, " Bulletin of the World Health Organization (2015): 93/2/15-152710.
11. J. A. Røttingen, S. Regmi, M. Eide, A. J. Young, R. F. Viergever, C. Årdal, J. Guzman, D. Edwards, S. A. Matlin, and R. F. Terry, "Mapping Available Health R&D Data: What's There, What's Missing and What Role for a Global Observatory, " The Lancet 382, no. 9900 (2013): 1286-1307.
12. K. Grogan, "AMR Review Head O'Neill Calls for $2 Billion Innovation Fund, " Pharma Times, available at (last visited May 14, 2015).
13. D. T. Jamison, L. H. Summers, and G. Alleyne et al., "Global Health 2035: A World Converging within a Generation, " The Lancet 382, no. 9908 (2013): 1898-1955.
14. President's Council of Advisors on Science & Technology, Report to the President on Combating Antibiotic-Resistant Bacteria (September 2014) at 3, available at (last visited May 14, 2015).
15. World Health Organization, "Innovation for Antibiotics Development and Preservation, " available at (last visited May 14, 2015).